Jamey Millar

Jamey Millar stated that Novo Nordisk pioneered the weight-loss drug category, with Wegovy pill achieving 17% weight loss efficacy and strong tolerability, and introduced a unique subscription model to improve adherence and affordability. These product advantages—superior efficacy, tolerability, and innovative consumer-centric pricing—are expected to sustain strong demand and market leadership, even as competitors like Eli Lilly enter the market. LONG on Novo Nordisk due to its first-mover edge, proven product performance, and strategic initiatives that enhance accessibility and patient retention in a growing market. Increased competition from Eli Lilly and other entrants, potential regulatory hurdles, adverse event reports, or shifts in consumer preference that could erode market share.